Trial Profile
A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Birinapant (Primary) ; Carboplatin; Docetaxel; Doxorubicin liposomal; Gemcitabine; Irinotecan; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 07 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 12 Jun 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 02 Jun 2013 Phase I results in 124 patients presented at ASCO 2103, according to a TetraLogic Pharmaceuticals media release.